Harrow Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Harrow wird ein Gewinn- und Umsatzwachstum von 73.6% bzw. 28.6% pro Jahr prognostiziert, während der Gewinn pro Aktie um 74.9% pro Jahr wachsen soll.

Wichtige Informationen

73.6%

Wachstumsrate der Gewinne

74.9%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	27.6%
Wachstumsrate der Einnahmen	28.6%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	06 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Harrow Health soars ~27% on FDA nod of anesthesia gel for the surface of the eye

Sep 27

SRK Capital - Harrow Health: Market Missing The Forest For The Trees

Aug 19

These 4 Measures Indicate That Harrow Health (NASDAQ:HROW) Is Using Debt Extensively

Aug 11

Buy Deep Moated, Fast Growing, Superbly Managed Harrow Health Ahead Of New Product Launch

May 23

Does Harrow Health (NASDAQ:HROW) Have A Healthy Balance Sheet?

May 12

Is Harrow Health (NASDAQ:HROW) A Risky Investment?

Dec 15

Does Harrow Health (NASDAQ:HROW) Have A Healthy Balance Sheet?

Aug 24

Harrow Health prices 8.625% senior notes due 2026

Jun 15

Harrow Health: An 8.3% Baby Bond Yield With Low Balance Sheet Leverage

May 28

Shareholders Shouldn’t Be Too Comfortable With Harrow Health's (NASDAQ:HROW) Strong Earnings

May 18

Harrow Health, Inc. (NASDAQ:HROW) Just Reported And Analysts Have Been Lifting Their Price Targets

Mar 11

Gewinn- und Umsatzwachstumsprognosen

NasdaqGM:HROW - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	350	86	N/A	N/A	1
12/31/2025	259	24	34	54	3
12/31/2024	185	-19	2	16	4
3/31/2024	139	-31	-14	7	N/A
12/31/2023	130	-24	-149	4	N/A
9/30/2023	114	-14	-167	-9	N/A
6/30/2023	103	-16	-147	-8	N/A
3/31/2023	93	-18	-146	-7	N/A
12/31/2022	89	-14	-6	2	N/A
9/30/2022	88	-23	-12	4	N/A
6/30/2022	84	-24	-13	2	N/A
3/31/2022	79	-21	-13	3	N/A
12/31/2021	72	-18	-11	5	N/A
9/30/2021	67	-10	4	6	N/A
6/30/2021	63	7	9	11	N/A
3/31/2021	52	10	2	3	N/A
12/31/2020	49	-3	-2	-1	N/A
9/30/2020	47	-2	-1	1	N/A
6/30/2020	45	-22	-3	-2	N/A
3/31/2020	51	-24	0	2	N/A
12/31/2019	51	0	-1	1	N/A
9/30/2019	50	16	-2	-1	N/A
6/30/2019	48	25	-3	0	N/A
3/31/2019	45	29	-2	0	N/A
12/31/2018	41	15	-2	1	N/A
9/30/2018	37	-6	-1	0	N/A
6/30/2018	33	-9	-3	-2	N/A
3/31/2018	30	-10	-7	-6	N/A
12/31/2017	27	-12	N/A	-9	N/A
9/30/2017	25	-15	N/A	-11	N/A
6/30/2017	24	-13	N/A	-12	N/A
3/31/2017	22	-20	N/A	-13	N/A
12/31/2016	20	-19	N/A	-11	N/A
9/30/2016	18	-18	N/A	-12	N/A
6/30/2016	15	-18	N/A	-11	N/A
3/31/2016	13	-17	N/A	-11	N/A
12/31/2015	10	-16	N/A	-11	N/A
9/30/2015	7	-14	N/A	-10	N/A
6/30/2015	5	-12	N/A	-9	N/A
3/31/2015	3	-11	N/A	-8	N/A
12/31/2014	2	-10	N/A	-7	N/A
9/30/2014	1	-9	N/A	-6	N/A
6/30/2014	1	-9	N/A	-6	N/A
3/31/2014	0	-9	N/A	-5	N/A
12/31/2013	0	-8	N/A	-4	N/A
9/30/2013	0	-7	N/A	-4	N/A
6/30/2013	0	-6	N/A	-3	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: HROW wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.4%).

Ertrag vs. Markt: HROW wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: HROW wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: HROWDie Einnahmen des Unternehmens (28.6% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: HROWDie Einnahmen des Unternehmens (28.6% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von HROW in 3 Jahren voraussichtlich hoch sein wird

Harrow Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates fall by 68%

Forecast breakeven date pushed back to 2025

Forecast breakeven date pushed back to 2024

Forecast breakeven date pushed back to 2024

Consensus forecasts updated

Consensus estimates of losses per share improve by 21%

Recent updates

Harrow, Inc. Announces 52-Week Data from VEVYE ESSENCE-2 Open-Label Extension Study

Consensus EPS estimates fall by 68%

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Harrow Names Greg Dipasquale as Senior Vice President, Head of Commercial

Harrow: The Bull Thesis Is On Track, But Short-Term Challenges Loom

Harrow, Inc., Annual General Meeting, Jun 14, 2024

Harrow, Inc. to Report Q1, 2024 Results on May 13, 2024

CEO & Chairman of the Board recently bought US$104k worth of stock

Forecast breakeven date pushed back to 2025

Full year 2023 earnings: EPS and revenues miss analyst expectations

Harrow, Inc. to Report Q4, 2023 Results on Mar 19, 2024

CEO & Chairman of the Board exercised options to buy US$1.1m worth of stock.

Harrow's Drug Iheezo Is Off To A Great Start

CEO & Chairman of the Board exercised options to buy US$166k worth of stock.

Harrow: Temporary Disruption In Stock Price Creates Excellent Opportunity

Harrow, Inc. Announces Board of Director Appointments

Harrow Announces Availability of Vevye® (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye Disease

Harrow, Inc. Completes Transfer of the TRIESENCE New Drug Application

CEO & Chairman of the Board recently bought US$61k worth of stock

New major risk - Financial position

Chief Commercial Officer exercised options and sold US$125k worth of stock

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Harrow, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Harrow, Inc. Completes Transfer of Ndas and Launches FLAREX, Natacyn St, Verkazia, and ZERVIATE in the U.S

Independent Director recently bought US$338k worth of stock

Forecast breakeven date pushed back to 2024

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Harrow Launches VIGAMOX in the U.S

CEO & Chairman of the Board exercised options and sold US$5.5m worth of stock

Harrow Health, Inc. to Report Q2, 2023 Results on Aug 09, 2023

First quarter 2023 earnings: EPS misses analyst expectations

Forecast breakeven date pushed back to 2024

Harrow Announces to Launch FDA-Approved IHEEZO at 2023 American Society of Cataract and Refractive Surgery Annual Meeting

CEO & Chairman of the Board exercised options and sold US$1.4m worth of stock

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Harrow Launches Next-Generation Compounded Atropine Formulations

An unknown buyer acquired all shares in Harrow Health, Inc. from SWK Funding LLC.

An unknown buyer acquired all shares in Harrow Health, Inc. from SWK Funding LLC.

Consensus forecasts updated

Harrow Health, Inc. Announces Availability of Fortisite Formulations for In-Office Use

CEO & Chairman of the Board exercised options and sold US$519k worth of stock

Chief of Formulation Strategy notifies of intention to sell stock

CEO & Chairman of the Board recently bought US$335k worth of stock

Harrow Health, Inc. has completed a Follow-on Equity Offering in the amount of $25.000002 million.

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Harrow Health, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Independent Director notifies of intention to sell stock

Harrow sells non‑ophthalmic compounding business, terms undisclosed

Harrow Health, Inc. and Sintetica, S.A. Announces U.S. FDA Approval of IHEEZO (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia

Harrow Health soars ~27% on FDA nod of anesthesia gel for the surface of the eye

SRK Capital - Harrow Health: Market Missing The Forest For The Trees

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

These 4 Measures Indicate That Harrow Health (NASDAQ:HROW) Is Using Debt Extensively

Harrow Health, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Harrow Health, Inc. Launches IOPIDINE 1% and MAXITROL in the United States

Buy Deep Moated, Fast Growing, Superbly Managed Harrow Health Ahead Of New Product Launch

Consensus estimates of losses per share improve by 21%

Does Harrow Health (NASDAQ:HROW) Have A Healthy Balance Sheet?

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Harrow Health, Inc. to Report Q1, 2022 Results on May 05, 2022

Harrow Health, Inc. Announces Management Changes

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Harrow Health, Inc. to Report Q4, 2021 Results on Mar 10, 2022

President of ImprimisRx exercised options and sold US$204k worth of stock

Harrow Health Announces FDA Acceptance of New Drug Application for AMP-100

CEO & Chairman of the Board exercised options and sold US$423k worth of stock

Is Harrow Health (NASDAQ:HROW) A Risky Investment?

Third quarter 2021 earnings released: US$0.31 loss per share (vs US$0.33 profit in 3Q 2020)

Price target increased to US$16.13